MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Finance & Investment / Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.
Old Articles: <Older 40421-40430 Newer>
The Motley Fool
February 25, 2010
Alyce Lomax
Keeping an Eye on Target Target's fourth-quarter results were more stylish than shabby. Is it time to snap up the retailer's shares? mark for My Articles 646 similar articles
The Motley Fool
February 25, 2010
Rich Smith
Time to Buy salesforce.com? If you are patient, you'll get a chance to own this superb stock at a significantly better price. mark for My Articles 355 similar articles
The Motley Fool
February 25, 2010
Anders Bylund
Apple Really Doesn't Do Computers Whether fuzzy math or not, it's clear that Apple is a top-tier mobile maven. mark for My Articles 370 similar articles
The Motley Fool
February 25, 2010
Selena Maranjian
Should We Support or Oppose This Change? A taxing question pits our taxpayer and shareholder sides against each other. "Check-the-box" tax rules permit multinational corporations to designate their international subsidiaries as "disregarded entities" for tax purposes. That helps these companies legally defer taxes. mark for My Articles 36 similar articles
The Motley Fool
February 25, 2010
Mike Pienciak
Waking Up to Gains The classic consumer name of Smucker's is still going strong. mark for My Articles 116 similar articles
The Motley Fool
February 25, 2010
Rick Aristotle Munarriz
NetEase Scores in the Fourth Quarter It was a quarter of redemption for China's online pioneer. mark for My Articles 219 similar articles
InternetNews
February 24, 2010
Salesforce Tops Q4 Estimates, Boosts Forecast The on-demand software leader didn't disappoint investors as it managed to top sales and earnings estimates in the fourth quarter and raised its guidance for the first quarter. mark for My Articles 971 similar articles
The Motley Fool
February 24, 2010
Brian Orelli
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. mark for My Articles 430 similar articles
The Motley Fool
February 24, 2010
April Taylor
A Triple Play for Your Portfolio? What do batteries, fertilizer, and emerging markets all have in common? Sociedad Quimica y Minera, one stock that you should consider, that's what. mark for My Articles 22 similar articles
The Motley Fool
February 24, 2010
David Lee Smith
It's Time to Take Oil Services Seriously With oil prices inching upward, costs are making service companies more attractive. mark for My Articles 552 similar articles
<Older 40421-40430 Newer>    Return to current articles.